Molecular docking analysis of Cianidanol from Ginkgo biloba with HER2+ breast cancer target

  • et al.
N/ACitations
Citations of this article
25Readers
Mendeley users who have this article in their library.

Abstract

HER2 is a known therapeutic target for about 30% of breast cancer patients where HER2 is over expressed and this is referred to as HER2 positive breast cancer. This subtype is characterized by a clinical behavior know to be especially aggressive. Improved HER2 targeting agents such as trastuzumab, pertuzumb, lapatinib and ado-trastuzumab emtansine are available. Some patients have shown no response to treatment while others show progress to these agents. Therefore, it is of interest to screen HER2+ with phyto-chemical lead compound from Ginkgo biloba using molecular docking techniques. We screened 25 phyto-chemicals from literature with HER2+. Results show that cianidanol have an acceptable binding energy of (-8.2kcal/mol). Thus, we report the binding properties of cianidanol with HER2+.

Cite

CITATION STYLE

APA

Arannilewa, A. J. … Ambrose, G. O. (2018). Molecular docking analysis of Cianidanol from Ginkgo biloba with HER2+ breast cancer target. Bioinformation, 14(9), 482–487. https://doi.org/10.6026/97320630014482

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free